SV Life Sciences flush with venture cash, bullish on exit deals

Boston-based SV Life Sciences, an active investor in the biotech scene, is flush with cash and its partners are practically bubbling with excitement over the improved prospects for cashing out of deals at a premium. SV garnered $523 million for its fifth life sciences fund, about $123 million over its target. And Managing Partner and Chief Executive James Garvey says that after a long dry spell, he's seeing a real shift in buyout strategies as acquirers start paying more for quality rather...